Technical Analysis for TGTX - TG Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
9.05 | 1.12% | 0.10 |
TGTX closed up 1.12 percent on Thursday, September 20, 2018, on 1.37 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical TGTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Sep 20 | Calm After Storm | Range Contraction | 0.00% |
| Sep 20 | Doji - Bullish? | Reversal | 0.00% |
| Sep 20 | Lower Bollinger Band Walk | Weakness | 0.00% |
| Sep 20 | Wide Bands | Range Expansion | 0.00% |
| Sep 20 | Lower Bollinger Band Touch | Weakness | 0.00% |
| Sep 20 | Oversold Stochastic | Weakness | 0.00% |
| Sep 19 | Calm After Storm | Range Contraction | 1.12% |
| Sep 19 | NR7 | Range Contraction | 1.12% |
| Sep 19 | Lower Bollinger Band Walk | Weakness | 1.12% |
| Sep 19 | Inside Day | Range Contraction | 1.12% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-08-08
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more TGTX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 17.35 |
| 52 Week Low | 7.25 |
| Average Volume | 1,098,868 |
| 200-Day Moving Average | 12.4432 |
| 50-Day Moving Average | 11.6975 |
| 20-Day Moving Average | 11.4288 |
| 10-Day Moving Average | 10.4075 |
| Average True Range | 0.6453 |
| ADX | 34.72 |
| +DI | 5.7798 |
| -DI | 35.7436 |
| Chandelier Exit (Long, 3 ATRs ) | 10.9641 |
| Chandelier Exit (Short, 3 ATRs ) | 10.5359 |
| Upper Bollinger Band | 14.0037 |
| Lower Bollinger Band | 8.8539 |
| Percent B (%b) | 0.04 |
| BandWidth | 45.059849 |
| MACD Line | -0.7508 |
| MACD Signal Line | -0.4157 |
| MACD Histogram | -0.3351 |
| Fundamentals | Value |
|---|---|
| Market Cap | 563.91 Million |
| Num Shares | 62.3 Million |
| EPS | -1.95 |
| Price-to-Earnings (P/E) Ratio | -4.64 |
| Price-to-Sales | 3189.49 |
| Price-to-Book | 6.24 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.95 | ||||
| Resistance 3 (R3) | 9.90 | 9.55 | 9.80 | ||
| Resistance 2 (R2) | 9.55 | 9.32 | 9.58 | 9.75 | |
| Resistance 1 (R1) | 9.30 | 9.18 | 9.43 | 9.35 | 9.70 |
| Pivot Point | 8.95 | 8.95 | 9.01 | 8.98 | 8.95 |
| Support 1 (S1) | 8.70 | 8.72 | 8.83 | 8.75 | 8.40 |
| Support 2 (S2) | 8.35 | 8.58 | 8.38 | 8.35 | |
| Support 3 (S3) | 8.10 | 8.35 | 8.30 | ||
| Support 4 (S4) | 8.15 |
